00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
04:47 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

Bavencio fails second ovarian cancer Phase III trial

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) discontinued the Phase III JAVELIN Ovarian 100 trial of Bavencio avelumab as first-line treatment of ovarian cancer after a planned interim analysis showed that the PD-L1 inhibitor would...
23:38 , Dec 21, 2018 |  BC Extra  |  Clinical News

Bavencio fails second ovarian cancer Phase III trial

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) discontinued the Phase III JAVELIN Ovarian 100 trial of Bavencio avelumab as first-line treatment of ovarian cancer after a planned interim analysis showed that the PD-L1 inhibitor would...
18:36 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Bavencio fails Phase III for ovarian cancer

Hopes for Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to get ahead in the ovarian cancer space, where no PD-1/PD-L1 inhibitors are approved, were delayed after the partners reported that PD-L1 inhibitor Bavencio avelumab missed...
00:53 , Nov 20, 2018 |  BC Extra  |  Clinical News

Bavencio fails Phase III for ovarian cancer

Hopes for Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to get ahead in the ovarian cancer space, where no PD-1/PD-L1 inhibitors are approved, were delayed Monday after the partners reported that PD-L1 inhibitor Bavencio avelumab...
18:25 , Nov 9, 2018 |  BC Week In Review  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
13:33 , Nov 6, 2018 |  BC Extra  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
18:13 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
18:10 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

After three deals, FDA approval, talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...